MedWatch

Aamund: The shareholders will thank us for our choice of strategy

The Chairman of Bavarian Nordic says there is a great interest in the company’s prostate cancer vaccine, Prostvac, on the market.

There is currently a “significant interest” in a collaboration concerning Bavarian Nordic’s candidate drug against prostate cancer, the vaccine prostvac, says Chairman of the board, Asger Aaamund, who is certain that the shareholders will someday thank the company’s management for the chosen strategy.

“We do not need a Prostvac partner right now, but Bavarian Nordic cannot take on the task of marketing Prostvac globally, and sooner or later we will obviously have to choose a partner in order to share the remaining development costs and to ensure a strong international market position,” Asger Aamund points out to Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier